Finance

Lists
Why is AMGN34 up 7,73%?
Dive Deeper
AMGN34:BVMF
Amgen Inc. BDR
R$84,89
+7,73%
(+6,09) 1D
26 Okt., 12:45:24 GMT-3  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for AMGN34...
Open
R$77,22
High
R$84,89
Low
R$77,22
Mkt. cap
238,25 mjd
Avg. vol.
391,00
Volume
5,00
52-wk high
R$84,89
52-wk low
R$47,76
Shares outstanding
540,63 m
No. of employees
32 k
Open
R$77,22
High
R$84,89
Low
R$77,22
Mkt. cap
238,25 mjd
Avg. vol.
391,00
Volume
5,00
52-wk high
R$84,89
52-wk low
R$47,76
Shares outstanding
540,63 m
No. of employees
32 k
News stories
From web sources and news partners
Profile
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics. The company's major products are Prolia and XGEVA to treat osteoporosis and bone diseases, Repatha to treat hyperlipidemia, Otezla to treat psoriasis and psoriatic arthritis, Enbrel to treat autoimmune diseases, Evenity to treat osteoporosis, Tepezza to treat Graves' ophthalmopathy, Blincyto to treat acute lymphoblastic leukemia, Nplate to regulate platelet production, Tezspire to treat asthma, Kyprolis to treat cancer, Aranesp to stimulate erythropoiesis, Krystexxa to treat gout, and Vectibix, a monoclonal antibody. Amgen has 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I. Its pipeline includes MariTide, an anti-obesity medication administered once per month by injection. The company receives approximately 80% of its revenues from sales to the three large U.S. drug wholesalers: McKesson Corporation, Cencora, and Cardinal Health. Wikipedia
About Amgen Inc. BDR
CEORobert A. Bradway
Employees31,5 k
Founded1980
HeadquartersThousand Oaks, Kalifornië, Verenigde State van Amerika
Sector-
Websiteamgen.com
Next call oor 8 dae
Di. 3 Nov., 23:30
Fiscal period
Q3 2026
- / USD 5,79
Revenue / Est. (USD)
- / 10,08 mjd
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
9,56 mjd
9,87 mjd
8,62 mjd
10,05 mjd
Cost of goods sold
2,74 mjd
2,68 mjd
2,50 mjd
2,75 mjd
Cost of revenue
2,74 mjd
2,68 mjd
2,50 mjd
2,75 mjd
Research and development expenses
1,90 mjd
2,14 mjd
1,72 mjd
1,87 mjd
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1,72 mjd
1,95 mjd
1,60 mjd
1,74 mjd
Operating expense
3,55 mjd
4,18 mjd
3,21 mjd
3,73 mjd
Total operating expenses
6,29 mjd
6,85 mjd
5,70 mjd
6,48 mjd
Operating income
3,26 mjd
3,01 mjd
2,91 mjd
3,57 mjd
Other non operating income
181,00 m
143,00 m
192,00 m
145,00 m
EBT including unusual items
3,92 mjd
1,51 mjd
2,08 mjd
2,77 mjd
EBT excluding unusual items
2,72 mjd
2,51 mjd
2,37 mjd
3,06 mjd
Income tax expense
705,00 m
181,00 m
265,00 m
393,00 m
Effective tax rate
17,98%
11,96%
12,72%
14,20%
Other operating expenses
-71,00 m
82,00 m
-113,00 m
116,00 m
Net income
3,22 mjd
1,33 mjd
1,82 mjd
2,38 mjd
Net profit margin
33,65%
13,51%
21,11%
23,62%
Earnings per share
5,64
5,29
5,15
6,29
Interest and investment income
-
408,00 m
-
-
Interest expense
-685,00 m
-1,06 mjd
-657,00 m
-673,00 m
Net interest expenses
-685,00 m
-653,00 m
-657,00 m
-673,00 m
Depreciation and amortization charges
-
-
-
-
EBITDA
4,57 mjd
4,02 mjd
4,03 mjd
4,69 mjd
Gain or loss from assets sale
-
-
-
-
Upcoming events
AI content may include mistakes. Learn more
Google-programme